Two proteins found on the surface of motor neurons in the brain may be essential in the progression of Parkinson’s disease, according to new Yale School of Medicine (YSM) research.
A research team from the Kunming Institute of Zoology (KIZ) of the Chinese Academy of Sciences has demonstrated for the first time in non-human primates that auditory stimulation at 40 Hz significantly elevates β-amyloid levels in the cerebrospinal fluid (CSF) of aged rhesus monkeys, with this effect persisting for over five weeks.
BrainSpace announced that the FDA granted 510(k) clearance for its Intellidrop automated brain fluid management system.
Ceribell (Nasdaq:CBLL) announced today that the FDA granted breakthrough device designation for its large vessel occlusion (LVO) stroke detection monitor.
A new international study has demonstrated that Alzheimer’s disease biomarkers can be accurately detected using simple finger-prick blood samples that can be collected at home and mailed to laboratories without refrigeration or prior processing.
Researchers at the Halle branch of the Fraunhofer Institute for Cell Therapy and Immunology IZI have identified a substance that selectively blocks harmful pathogens such as Porphyromonas gingivalis without affecting other bacteria.
ABBOTT PARK, Ill., Jan. 5, 2026 /PRNewswire/ — Abbott (NYSE: ABT), a leading healthcare company, today unveiled Libre Assist,1 a groundbreaking feature within the Libre app5 designed to help the millions of people living with diabetes in the U.S. better understand how the foods they eat affect their glucose levels. 1,2 Unlike traditional food logging apps that only give feedback after a meal is logged, Libre Assist1 helps people make informed mealtime decisions before they eat. Abbott is launching the new technology during CES 2026 in Las Vegas.
Professor Jung Kyoon Choi’s research team from the Department of Bio and Brain Engineering, in collaboration with Neogen Logic Co., Ltd., developed the new AI model to predict neoantigens.
A major new study has found that transcranial magnetic stimulation (TMS), which applies magnetic energy to the brain, can be a cost-effective treatment option for the NHS in treating moderate and severe forms of depression that have not responded to other treatments.
Researchers at the Francis Crick Institute and AlveoliX have developed the first human lung-on-chip model using stem cells taken from only one person.